AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients

Plain-language summary

This observational study monitored, in real-life conditions, the effectiveness of and resistance to anti-cytomegalovirus (CMV) medicines in patients receiving hematopoietic stem cell transplants. Adults for whom a decision to perform an allogeneic stem cell transplant had been made and who were willing to participate were included. This study without an assigned phase has been carried out and is completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University Hospital, Limoges

Intervention

Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients

Start date

9/24/2020

Estimated completion

11/30/2025

Countries

France

Related genes

Locations

• Limoges, France
• Amiens, France
• Angers, France
• Besançon, France
• Bordeaux, France
• Caen, France
• Clermont-Ferrand, France
• Grenoble, France
• Lyon, France
• Montpellier, France
• Nancy, France
• Paris, France
• Poitiers, France
• Rouen, France
• Saint-Etienne, France
• Strasbourg, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria :

• Candidate (adult) for an allograft of hematopoietic stem cells for which a decision of transplant is made and willing to participate in the cohort.

Exclusion Criteria :

* CMV-seronegative patient receiving a negative CMV donor graft ;
* Patient having signed the consent but not grafted ;
* Patient included in a clinical study on an anti-CMV molecule ;
* Non-insured social patient ;